GLP-1 Drugs Work on the Brain. Surgeons Are Starting to Ask What Else They’re Changing.

What Forty Million Prescriptions Don’t Fully Explain

GLP-1 receptor agonists — semaglutide, tirzepatide, and their relatives — are now prescribed to an estimated 40 million Americans. The mechanism driving their use is well understood: these drugs mimic glucagon-like peptide-1, a gut hormone that regulates blood sugar, slows gastric emptying, and signals satiety. The weight loss follows from that last function. Appetite decreases. Caloric intake drops. The metabolic outcome is documented across large-scale trials.

What is less settled is what happens further upstream. GLP-1 receptors are expressed not just in the pancreas and gut, but throughout the central nervous system — including the ventral tegmental area and nucleus accumbens, structures that govern reward, motivation, and the neurological architecture of addiction. Researchers have been studying this for years. Clinicians are now beginning to ask what it means at scale.

The Perioperative Problem Surgeons Solved First

Before the neurological questions became mainstream, a more immediate concern surfaced in operating rooms. Patients on semaglutide were arriving for elective procedures having fasted appropriately — and still presenting with residual gastric contents. Several case reports described aspiration events during general anesthesia in patients who had followed standard preoperative fasting protocols to the letter.

The mechanism is direct: GLP-1 receptor agonists delay gastric emptying. The effect generally diminishes with long-term use, but it does not disappear entirely, and its magnitude varies by patient and dosing schedule. Semaglutide’s half-life of approximately seven days complicates the math further.

In June 2023, the American Society of Anesthesiologists issued guidance recommending that patients hold daily GLP-1 medications on the day of surgery and weekly injections for a full week beforehand. By October 2024, the ASA reversed course — joining a multisociety consensus statement concluding that most stable, long-term patients can continue their medications into the perioperative period, provided the clinical team is informed and appropriate precautions are taken. The reversal reflected accumulating data, not a fundamental change in the underlying biology. Gastric motility remains a variable that anesthesiologists now systematically account for in a way they did not five years ago.

Dopamine, Reward, and the Questions Nobody Has Answered Yet

The neurological dimension moves more slowly and with less clinical urgency — but the research is accelerating. The core observation driving interest is that GLP-1 receptors in the ventral tegmental area appear to modulate dopamine signaling in ways that extend well beyond food reward. A 2024 study in Neuroscience Applied found that semaglutide reduced appetite while simultaneously altering dopamine activity during reward-consumption phases in mouse models — not suppressing reward-seeking behavior, but changing the quality and timing of the dopamine response.

What this means for human behavior is not yet clearly established. A trial published in The Lancet Psychiatry in October 2024 found that semaglutide reduced relapse rates in alcohol use disorder by 28 percent compared to placebo over 26 weeks, across 547 participants at six clinical sites. Some researchers interpret this as evidence that GLP-1 agonists are modulating addiction pathways in clinically meaningful ways. Others caution that the mechanism is not well enough understood to draw firm conclusions — that the observed effects may reflect downstream consequences of appetite suppression or metabolic changes rather than direct CNS action.

A separate study published in Nature Metabolism in November 2025 added a complicating data point: semaglutide reduced dopamine release in response to food stimuli in a cohort of 84 adults, but also measurably blunted responses to non-food rewards, including social interaction scores on standardized assessments. The implication — that the drug may affect motivational salience across reward categories, not just eating — has drawn attention from neuropsychopharmacologists who study mood disorders and hedonic processing.

Neuroprotection: The More Favorable Signal

Not all the neurological data raises questions. A substantial and growing body of preclinical work suggests GLP-1 receptor agonists may have neuroprotective properties. In Alzheimer’s disease models, liraglutide and semaglutide have shown capacity to reduce amyloid-β plaque accumulation and inhibit tau hyperphosphorylation. The ELAD trial — a randomized, double-blind, placebo-controlled study of 204 patients with mild Alzheimer’s disease — found that liraglutide treatment resulted in nearly 50 percent less brain volume loss in frontal, temporal, and parietal regions compared to placebo.

In Parkinson’s disease models, GLP-1 receptor agonists have demonstrated capacity to reduce alpha-synuclein aggregation and support dopaminergic neuron survival through anti-apoptotic signaling. The EVOKE and EVOKE+ trials are now evaluating oral semaglutide in patients aged 55 to 85 with mild cognitive impairment or early Alzheimer’s pathology — the first large-scale phase 3 studies testing GLP-1 RAs against neurodegeneration in humans.

Whether these effects translate meaningfully from animal models and early-phase human trials to clinical practice remains to be established. The biology is encouraging. The evidence base is not yet sufficient to change practice.

What the Scale of Use Is Forcing

Academic interest in GLP-1 neurology predates the current prescription surge. What has changed is the population under observation. When 40 million people take a drug that demonstrably affects CNS dopamine pathways, the population-level implications of even modest neurological effects become clinically significant. Researchers who might otherwise publish incremental findings in specialty journals are now addressing questions that affect primary care, psychiatry, and neurology simultaneously.

The practical consequence is that medicine is running an unusually large naturalistic experiment — not by design, but because the metabolic indications for these drugs are clear and the prescribing has outpaced the full characterization of their effects. Anesthesiologists solved their immediate problem. Neurologists are still mapping the territory.

The honest summary of where the science stands: GLP-1 receptor agonists affect the brain in ways that are real, measurable, and not fully understood. The perioperative questions have working answers. The questions about reward, motivation, mood, and long-term CNS effects do not — and the researchers positioned to answer them are working with an urgency proportional to the drugs’ reach.

You Might Also Like

• The Leather Briefcase: A Symbol of Professionalism and Style
• Why Lawyers Still Wear Watches Nobody Can See on Zoom
• Dressed for the Bench: What Judges Actually Notice About How Lawyers Look

Sources

• IQVIA Institute for Human Data Science — GLP-1 prescription volume estimates, Q1 2026
• American Society of Anesthesiologists — Consensus-Based Guidance on Preoperative Management of Patients on GLP-1 Receptor Agonists, June 2023: asahq.org
• Kindel TL et al. — “Multisociety Clinical Practice Guidance for the Safe Use of GLP-1 Receptor Agonists in the Perioperative Period,” Surgical Endoscopy, 2025: PMC
• Kooij et al. — “GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling,” Neuroscience Applied, 2024
• The Lancet Psychiatry — Semaglutide and alcohol use disorder relapse, October 2024
• Nature Metabolism — Semaglutide and non-food reward blunting, November 2025 (via Altitudes Magazine, April 2026): altitudesmagazine.com
• PMC — “From metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics,” 2025: PMC
• PMC — “Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)”: PMC
• NeurologyLive — “Repositioning GLP-1 Drugs for Neurologic Disease,” May 2026: neurologylive.com